This conclusion is particularly compelling when the experimental data (cell line and clinical studies) is compared to the meta-analysis of ID4 promoter (UCSC genome browser) and remarkable mutually exclusive expression profile of EZH2 and ID4 in prostate cancer (TCGA datasets and experimental evidence). The gene discussed is ID4; the disease is prostate carcinoma.